Connor, Clark & Lunn Investment Management (CC&L)
ELDN icon

Connor, Clark & Lunn Investment Management (CC&L)’s Eledon Pharmaceuticals ELDN Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-11,303
Closed -$46.6K – 1466
2024
Q4 		$46.6K Buy
+11,303
New +$44.6K ﹤0.01% 1374

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ELDN Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Eledon Pharmaceuticals (ELDN) in Q1 2025, closing a stake of 11,303 shares — an estimated $46.6K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ELDN in Q4 2024 and held it in 1 quarter. The position peaked at $46.6K in Q4 2024. 83 funds tracked by Wall St. Rank hold ELDN as of Q1 2025.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Eledon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 11,303 Eledon Pharmaceuticals shares in Q1 2025, an estimated $46.6K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Eledon Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Eledon Pharmaceuticals position peaked at $46.6K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.